Shots:
- The EC has approved Hetronifly + CT (carboplatin & etoposide) as a 1L treatment for extensive-stage small cell lung cancer (ES-SCLC) pts.
- Serplulimab, an anti-PD-1 mAb for 1L SCLC therapy, is approved in China and several SEA countries. ESMO rates it 4/5 on the MCBS for ES-SCLC. Its trial results were published in JAMA, Nature Medicine, Cancer Cell, and the British Journal of Cancer
- Henlius partnered with Intas in 2023 to develop and commercialize Hetronifly in more than 50 countries across EU and India. Intas’ subsidiary, Accord Healthcare, will lead the commercialization in EU & EEA countries (Norway, Iceland, and Liechtenstein)
Ref: Prnewswire | Image: Henlius & Intas
Related News:- Henlius and Intas’ Hetronifly (Serplulimab) Receives the CHMP’s Positive Opinion to Treat Extensive-Stage SCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
